Loading clinical trials...
Loading clinical trials...
Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy
Conditions
Locations
37
Canada
Location n°31
Mississauga - Chow, Canada
Location n°36
Ontario, Canada
Location n°34
Rimouski, Canada
Location n°33
Saskatchewan, Canada
Location n°35
Toronto, Canada
Location n°41
Amiens, France
Start Date
February 1, 2011
Primary Completion Date
October 1, 2012
Completion Date
October 1, 2012
Last Updated
February 1, 2013
NCT07484243
NCT06647069
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
TcLand Expression S.A.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions